×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

 

Taking on KRAS

Amgen is leading the pursuit to solve one of cancer research’s toughest challenges.



Targeting the KRAS protein has been one of cancer research’s toughest challenges of the last 40 years.1,2

Through the ongoing CodeBreaK clinical trials, Amgen is currently exploring the potential of KRASG12C inhibition across multiple tumor types with the KRASG12C mutation, with the goal of advancing care for seriously ill patients.

Learn more about how Amgen is pioneering the latest research in KRAS G12C.

References

  1. Cox AD, et al. Nat Rev Drug Discov. 2014;13:828-851.
  2. Fernandez-Medarde A, et al. Genes Cancer. 2011;2:344-358.